iData Insights

Acute Lung Injury - Pipeline Review, H2 2015 Is Released

Press Release   •   Feb 02, 2016 19:05 IST

This report provides comprehensive information on the therapeutic development for Acute Lung Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lung Injury and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Lung Injury - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Lung Injury and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acute Lung Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acute Lung Injury pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Lung Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Lung Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179112/acute-lung-injury-pipeline-review-h2-2015

To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179112/acute-lung-injury-pipeline-review-h2-2015

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Acute Lung Injury Overview 10

Therapeutics Development 11

Pipeline Products for Acute Lung Injury - Overview 11

Pipeline Products for Acute Lung Injury - Comparative Analysis 12

Acute Lung Injury - Therapeutics under Development by Companies 13

Acute Lung Injury - Therapeutics under Investigation by Universities/Institutes 15

Acute Lung Injury - Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Acute Lung Injury - Products under Development by Companies 18

Acute Lung Injury - Products under Investigation by Universities/Institutes 20

Acute Lung Injury - Companies Involved in Therapeutics Development 21

Altor BioScience Corporation 21

Apeptico Forschung und Entwicklung GmbH 22

Bayer AG 23

BioMarck Pharmaceuticals, Ltd. 24

Carolus Therapeutics, Inc. 25

CompleGen, Inc. 26

FirstString Research, Inc. 27

GlaxoSmithKline Plc 28

Histocell S.L. 29

Navigen Pharmaceuticals, Inc. 30

Noxxon Pharma AG 31

Quark Pharmaceuticals, Inc. 32

S-Evans Biosciences, Inc. 33

Silence Therapeutics Plc 34

Stemedica Cell Technologies, Inc. 35

Xiber Science GmbH 36

Acute Lung Injury - Therapeutics Assessment 37

Assessment by Monotherapy Products 37

Assessment by Target 38

Assessment by Mechanism of Action 40

Assessment by Route of Administration 42

Assessment by Molecule Type 44

Drug Profiles 46

ALT-836 - Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Atu-111 - Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Atu-112 - Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

BAY-858501 - Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

BC-1215 - Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

BIO-10901 - Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

CGX-1037 - Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

CMB-200 - Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

CT-2009 - Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Drugs to Antagonize IGF-1 Receptor for Acute Lung Injury and Pulmonary Fibrosis - Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Drugs to Inhibit Adenosine A1 Receptor for Lung Injury and Lung Inflammation - Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

GSK-2586881 - Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

GSK-2862277 - Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

HC-016 - Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

LTI-02 - Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

MG-53 - Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

NAV-2729 - Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

NOXD-19 - Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension - Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

P- BEFizumab - Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

Peptide to Activate PAI-1 for Acute Lung Injury - Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

QPLI-2 - Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

S-1229 - Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

solnatide - Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Stem Cell Therapy for Acute Lung Injury - Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Stem Cell Therapy for Inflammatory Lung Diseases - Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders - Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Stromal Cell Therapy for Acute Lung Injury - Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

Synthetic Peptides for Respiratory Distress Syndrome and Acute Lung Injury - Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

TXA-302 - Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

Xib-1301 - Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

Acute Lung Injury - Recent Pipeline Updates 93

Acute Lung Injury - Dormant Projects 98

Read More http://www.idatainsights.com/reports-landing-page.php?id=179112/acute-lung-injury-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.